STOCK TITAN

Immunocore to present at upcoming investor conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Immunocore Holdings Plc (Nasdaq: IMCR) announces upcoming presentations at key investor conferences in March 2023, focusing on its pioneering T cell receptor (TCR) bispecific immunotherapies. The conferences include:

  • Cowen 43rd Annual Health Care Conference on March 6 at 1:30 p.m. ET
  • Oppenheimer 33rd Annual Healthcare Conference on March 14 at 8:00 a.m. ET
  • Barclays Global Healthcare Conference on March 15 at 3:35 p.m. ET
  • Jefferies Biotech on the Bay Summit on March 16, 2023

Live webcasts of the presentations will be available on Immunocore's website.

Positive
  • None.
Negative
  • None.

Immunocore to present at upcoming investor conferences

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 28 February 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, autoimmune, and infectious diseases, today announced that management will present at the following upcoming investor conferences in March:

  • Cowen 43rd Annual Health Care Conference
    Fireside Chat: Monday, March 6, 2023, at 1:30 p.m. ET
  • Oppenheimer 33rd Annual Healthcare Conference
    Presentation: Tuesday, March 14, 2023, at 8:00 a.m. ET
  • Barclays Global Healthcare Conference
    Fireside Chat: Wednesday, March 15, 2023, at 3:35 p.m. ET
  • Jefferies Biotech on the Bay Summit
    1x1 and small group meetings: Thursday, March 16, 2023

The presentations will be webcast live and will be available in the ‘Investors’ section of Immunocore’s website at www.immunocore.com. A replay of the presentations will be made available for a limited time.

##

About Immunocore

Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune, and infectious disease. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. The Company’s most advanced oncology TCR therapeutic, KIMMTRAK has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.

CONTACT: 

Immunocore
Sébastien Desprez, Head of Communications
T: +44 (0) 7458030732
E: sebastien.desprez@immunocore.com
Follow on Twitter: @Immunocore
Consilium Strategic Communications (corporate and financial)
Mary-Jane Elliott/ Chris Welsh/Jessica Hodgson
T: +44 (0)203 709 5700
E: Immunocore@consilium-comms.com

Investor Relations  
Clayton Robertson, Head of Investor Relations
T: +1 215-384-4781
E: ir@immunocore.com


FAQ

What is Immunocore's stock symbol?

Immunocore's stock symbol is IMCR.

When will Immunocore present at the Cowen conference?

Immunocore will present at the Cowen 43rd Annual Health Care Conference on March 6, 2023, at 1:30 p.m. ET.

What is the focus of Immunocore's investor presentations?

Immunocore's investor presentations will focus on its T cell receptor bispecific immunotherapies.

How can I watch Immunocore's conference presentations?

You can watch Immunocore's conference presentations live on their website in the 'Investors' section.

What is the schedule for Immunocore's upcoming conferences?

Immunocore will present at the following conferences: Cowen on March 6, Oppenheimer on March 14, Barclays on March 15, and Jefferies on March 16, 2023.

Immunocore Holdings plc American Depositary Shares

NASDAQ:IMCR

IMCR Rankings

IMCR Latest News

IMCR Stock Data

1.49B
45.35M
5.24%
94.47%
14.1%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
OXFORDSHIRE